Hepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide, with 800,000 deaths per year. Since surgical options for HCC patients are limited, minimally invasive ablative therapies are critical to treat early-stage HCC; however, their cost and need for specialized equipment and expertise prevent widespread use in underprivileged populations. Here, we propose a lower-cost Light-Activatable, Sustained-exposure Ethanol Injection Technology (LASEIT) to augment current options for underprivileged patients.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.